|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The hub genes, including membrane palmitoylated protein 7, aldehyde dehydrogenase 6 family member A1, transcription factor AP‑2α, collagen type IV α 4 chain, nuclear receptor subfamily 3 group C member 2, plasminogen, Holliday junction recognition protein, claudin 10, kinesin family member 18B and thyroid hormone receptor β, and the hub miRNAs, including miR‑21‑3p, miR‑155‑3p, miR‑144‑3p, miR‑142‑5p, miR‑875‑3p, miR‑885‑3p, miR‑3941, miR‑224‑3p, miR‑584‑3p and miR‑138‑1‑3p, were significantly associated with CCRCC survival.
|
31746384 |
2020 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The survival analysis of the hub genes showed that KIRC patients with high gene expression of C2, MXRA8, TNFSF13B, and X-linked inhibitor of apoptosis protein-associated factor 1 (XAF1) had worse overall survival, and MXRA8, TNFSF13B, and XAF1 alteration were significantly associated with disease-free survival (DFS).
|
31697440 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The identified hub genes facilitate our knowledge of the underlying molecular mechanism of how Treg cells affect ccRCC in anti-tumor immune therapy.
|
31672930 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
In addition, by using survival analysis, we found that patients of ccRCC with high expression of each hub gene were more likely to have poor prognosis than those with low expression.
|
30417363 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Survival analysis showed a higher expression or lower methylation of these hub genes, a longer survival of ccRCC patients. ccRCC samples with higher expression of hub genes were enriched in gene sets correlated with signaling like biosynthesis of unsaturated fatty acids, butanoate metabolism, and PPAR signaling pathway.
|
31839812 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of certain hub genes (CDKN3, TPX2, BUB1B, CDCA8, UBE2C, NDC80, RRM2, NCAPG, NCAPH, PTTG1, FAM64A, ANLN, KIF4A, CEP55, CENPF, KIF20A, ASPM and HJURP) were significantly associated with overall survival and recurrence-free survival in ccRCC.
|
30988807 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Literature retrieval results showed the hub gene NDC80, CENPE and ACADM might be novel targets for the diagnosis, clinical treatment and prognosis of ccRCC.
|
31788359 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
UALCAN web-portal was used for expression validation and survival analysis of hub genes in ccRCC patients from The Cancer Genome Atlas (TCGA).
|
30008862 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
These 29 hub genes were subsequently validated using 2 other independent datasets including GSE53757 (<i>n</i> = 72) and TCGA (<i>n</i> = 530), and the results indicated that all hub genes were significantly positive correlated with the 4 stages of ccRCC progression.
|
29720944 |
2018 |